tiprankstipranks
Trending News
More News >
Astellas Pharma (ALPMF)
:ALPMF
US Market
Advertisement

Astellas Pharma (ALPMF) Stock Forecast & Price Target

Compare
51 Followers
See the Price Targets and Ratings of:

ALPMF Analyst Ratings

Moderate Buy
3Ratings
Moderate Buy
2 Buy
1 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Astellas
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ALPMF Stock 12 Month Forecast

Average Price Target

$11.96
▲(19.60%Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Astellas Pharma in the last 3 months. The average price target is $11.96 with a high forecast of $14.90 and a low forecast of $10.16. The average price target represents a 19.60% change from the last price of $10.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","15":"$15","9.75":"$9.75","11.5":"$11.5","13.25":"$13.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.16</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,9.75,11.5,13.25,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.64,10.044615384615385,10.44923076923077,10.853846153846154,11.258461538461539,11.663076923076924,12.067692307692308,12.472307692307693,12.876923076923077,13.281538461538462,13.686153846153847,14.090769230769231,14.495384615384616,{"y":14.9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.64,9.81846153846154,9.996923076923078,10.175384615384615,10.353846153846154,10.532307692307693,10.710769230769232,10.88923076923077,11.067692307692308,11.246153846153847,11.424615384615386,11.603076923076923,11.781538461538462,{"y":11.96,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.64,9.68,9.72,9.76,9.8,9.84,9.88,9.92,9.96,10,10.040000000000001,10.08,10.120000000000001,{"y":10.16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.54,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.34,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.88,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.6,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.62,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.37,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.62,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.51,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.71,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.95,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.64,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$14.90Average Price Target$11.96Lowest Price Target$10.16
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on ALPMF
Shinichiro MuraokaMorgan Stanley
Morgan Stanley
$10.16
Hold
1.58%
Upside
Reiterated
05/30/25
Morgan Stanley Sticks to Its Hold Rating for Astellas Pharma (ALPMF)
Bernstein Analyst forecast on ALPMF
Miki SogiBernstein
Bernstein
$12.87$10.84
Buy
8.35%
Upside
Reiterated
05/08/25
Analysts Offer Insights on Healthcare Companies: aTyr Pharma (NASDAQ: ATYR), Vir Biotechnology (NASDAQ: VIR) and Astellas Pharma (Other OTC: ALPMF)
Citi
$16.25$14.9
Buy
48.98%
Upside
Reiterated
05/01/25
Astellas Pharma Inc (4503:JP) (ALPMY) PT Lowered to JPY2,200 at CitiCiti analyst Hidemaru Yamaguchi lowered the price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) to JPY2,200.00 (from JPY2,400.00) while maintaining a Buy rating.
Jefferies
$10.16
Hold
1.58%
Upside
Reiterated
04/24/25
Analysts Offer Insights on Healthcare Companies: Astellas Pharma (Other OTC: ALPMF), Penumbra (NYSE: PEN) and Genmab (NASDAQ: GMAB)
J.P. Morgan Analyst forecast on ALPMF
Seiji WakaoJ.P. Morgan
J.P. Morgan
$11.65$11.51
Hold
15.12%
Upside
Reiterated
03/05/25
J.P. Morgan Remains a Hold on Astellas Pharma (ALPMF)
Macquarie Analyst forecast on ALPMF
Tony RenMacquarie
Macquarie
$14.9$13.54
Buy
35.44%
Upside
Reiterated
02/11/25
Astellas Pharma Inc (4503:JP) (ALPMY) PT Lowered to JPY2,000 at MacquarieMacquarie analyst Tony Ren lowered the price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) to JPY2,000.00 (from JPY2,200.00) while maintaining a Outperform rating.
Nomura
$15.58$14.22
Buy
42.21%
Upside
Reiterated
10/31/24
Astellas Pharma Inc (4503:JP) (ALPMY) PT Lowered to JPY2,100 at Nomura/InstinetNomura/Instinet analyst Motoya Kohtani lowered the price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) to JPY2,100.00 (from JPY2,300.00) while maintaining a Buy rating.
UBS
$12.87
Hold
28.67%
Upside
Reiterated
09/28/24
UBS Reiterates Neutral Rating on Astellas Pharma Inc (4503:JP) (ALPMY)UBS analyst Kasumi Haruta reiterated a Neutral rating and JPY1,900.00 price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY).
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on ALPMF
Shinichiro MuraokaMorgan Stanley
Morgan Stanley
$10.16
Hold
1.58%
Upside
Reiterated
05/30/25
Morgan Stanley Sticks to Its Hold Rating for Astellas Pharma (ALPMF)
Bernstein Analyst forecast on ALPMF
Miki SogiBernstein
Bernstein
$12.87$10.84
Buy
8.35%
Upside
Reiterated
05/08/25
Analysts Offer Insights on Healthcare Companies: aTyr Pharma (NASDAQ: ATYR), Vir Biotechnology (NASDAQ: VIR) and Astellas Pharma (Other OTC: ALPMF)
Citi
$16.25$14.9
Buy
48.98%
Upside
Reiterated
05/01/25
Astellas Pharma Inc (4503:JP) (ALPMY) PT Lowered to JPY2,200 at CitiCiti analyst Hidemaru Yamaguchi lowered the price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) to JPY2,200.00 (from JPY2,400.00) while maintaining a Buy rating.
Jefferies
$10.16
Hold
1.58%
Upside
Reiterated
04/24/25
Analysts Offer Insights on Healthcare Companies: Astellas Pharma (Other OTC: ALPMF), Penumbra (NYSE: PEN) and Genmab (NASDAQ: GMAB)
J.P. Morgan Analyst forecast on ALPMF
Seiji WakaoJ.P. Morgan
J.P. Morgan
$11.65$11.51
Hold
15.12%
Upside
Reiterated
03/05/25
J.P. Morgan Remains a Hold on Astellas Pharma (ALPMF)
Macquarie Analyst forecast on ALPMF
Tony RenMacquarie
Macquarie
$14.9$13.54
Buy
35.44%
Upside
Reiterated
02/11/25
Astellas Pharma Inc (4503:JP) (ALPMY) PT Lowered to JPY2,000 at MacquarieMacquarie analyst Tony Ren lowered the price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) to JPY2,000.00 (from JPY2,200.00) while maintaining a Outperform rating.
Nomura
$15.58$14.22
Buy
42.21%
Upside
Reiterated
10/31/24
Astellas Pharma Inc (4503:JP) (ALPMY) PT Lowered to JPY2,100 at Nomura/InstinetNomura/Instinet analyst Motoya Kohtani lowered the price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY) to JPY2,100.00 (from JPY2,300.00) while maintaining a Buy rating.
UBS
$12.87
Hold
28.67%
Upside
Reiterated
09/28/24
UBS Reiterates Neutral Rating on Astellas Pharma Inc (4503:JP) (ALPMY)UBS analyst Kasumi Haruta reiterated a Neutral rating and JPY1,900.00 price target on Astellas Pharma Inc (4503:JP) (OTC: ALPMY).
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Astellas Pharma

1 Month
xxx
Success Rate
3/6 ratings generated profit
50%
Average Return
+0.15%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +0.15% per trade.
3 Months
xxx
Success Rate
1/6 ratings generated profit
17%
Average Return
-4.03%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 16.67% of your transactions generating a profit, with an average return of -4.03% per trade.
1 Year
Miki SogiBernstein
Success Rate
3/6 ratings generated profit
50%
Average Return
+1.38%
reiterated a buy rating 3 months ago
Copying Miki Sogi's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +1.38% per trade.
2 Years
xxx
Success Rate
3/6 ratings generated profit
50%
Average Return
+1.38%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +1.38% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALPMF Analyst Recommendation Trends

Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
3
2
3
5
6
Buy
0
0
0
0
0
Hold
3
2
3
2
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
4
6
7
7
In the current month, ALPMF has received 6 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ALPMF average Analyst price target in the past 3 months is 11.96.
Each month's total comprises the sum of three months' worth of ratings.

ALPMF Financial Forecast

ALPMF Earnings Forecast

Next quarter’s earnings estimate for ALPMF is $0.13 with a range of $0.07 to $0.20. The previous quarter’s EPS was $0.28. ALPMF beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.93% of the time in the same period. In the last calendar year ALPMF has Outperformed its overall industry.
Next quarter’s earnings estimate for ALPMF is $0.13 with a range of $0.07 to $0.20. The previous quarter’s EPS was $0.28. ALPMF beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.93% of the time in the same period. In the last calendar year ALPMF has Outperformed its overall industry.

ALPMF Sales Forecast

Next quarter’s sales forecast for ALPMF is $3.08B with a range of $2.54B to $3.30B. The previous quarter’s sales results were $3.11B. ALPMF beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.39% of the time in the same period. In the last calendar year ALPMF has Outperformed its overall industry.
Next quarter’s sales forecast for ALPMF is $3.08B with a range of $2.54B to $3.30B. The previous quarter’s sales results were $3.11B. ALPMF beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.39% of the time in the same period. In the last calendar year ALPMF has Outperformed its overall industry.

ALPMF Stock Forecast FAQ

What is ALPMF’s average 12-month price target, according to analysts?
Based on analyst ratings, Astellas Pharma’s 12-month average price target is 11.96.
    What is ALPMF’s upside potential, based on the analysts’ average price target?
    Astellas Pharma has 19.60% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ALPMF a Buy, Sell or Hold?
          Astellas Pharma has a consensus rating of Moderate Buy which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Astellas Pharma’s price target?
            The average price target for Astellas Pharma is 11.96. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $14.90 ,the lowest forecast is $10.16. The average price target represents 19.60% Increase from the current price of $10.
              What do analysts say about Astellas Pharma?
              Astellas Pharma’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of ALPMF?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis